Showing results (1-10 of 51) with videos related to
Sort By:
Pageof 6
Pharmaceutical Research|September 24, 2005
The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant KmJoe Bentz, Thuy Thanh Tran, Joseph W Polli, et al.Pharmaceutical Research|May 20, 2003
Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrateSanna Tolle-Sander, Jarkko Rautio, Steve Wring, et al.Toxicologic Pathology|September 8, 2018
New Frontiers: Approaches to Understand the Mechanistic Basis of Renal ToxicityMary B Nabity, Joseph W Polli, Vishal Vaidya, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 19, 2013
Understanding the transport properties of metabolites: case studies and considerations for drug developmentMaciej J Zamek-Gliszczynski, Xiaoyan Chu, Joseph W Polli, et al.Biochemistry|December 21, 2006
P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sitesPoulomi Acharya, Thuy T Tran, Joseph W Polli, et al.Bioanalysis|February 19, 2013
Conference report: a hitchhiker's guide to outsourcing ADME studies: the inside of outsourcingJ Fred Pritchard, Shelby R Anderson, Claudia Breuckner, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 31, 2007
Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cellsPoulomi Acharya, Michael P O'Connor, Joseph W Polli, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 6, 2009
If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?Annie Albin Lumen, Poulomi Acharya, Joseph W Polli, et al.The Journal of Pharmacology and Experimental Therapeutics|June 9, 2019
Mechanistic Basis of Cabotegravir-Glucuronide Disposition in HumansMitesh Patel, H Christian Eberl, Andrea Wolf, et al.Journal of Pharmaceutical Sciences|March 5, 2004
Predicting P-glycoprotein substrates by a quantitative structure-activity relationship modelVijay K Gombar, Joseph W Polli, Joan E Humphreys, et al.Pageof 6